{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:03:13Z","timestamp":1779116593209,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.eururo.2011.07.008","type":"journal-article","created":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T06:25:24Z","timestamp":1311056724000},"page":"1273-1279","source":"Crossref","is-referenced-by-count":66,"title":["Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib"],"prefix":"10.1016","volume":"60","author":[{"given":"E. Jason","family":"Abel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Culp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pheroze","family":"Tamboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.07.008_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0010","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0015","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/cncr.25046","article-title":"Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?","volume":"116","author":"Culp","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.07.008_bib0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2009.0045","article-title":"New treatments for renal cell carcinoma: targeted therapies","volume":"7","author":"Saylor","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2011.07.008_bib0025","unstructured":"Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). ClinicalTrials.gov Web site. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00930033."},{"key":"10.1016\/j.eururo.2011.07.008_bib0030","unstructured":"Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer. ClinicalTrials.gov Web site. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01099423."},{"key":"10.1016\/j.eururo.2011.07.008_bib0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2010.09.034","article-title":"Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma","volume":"59","author":"Abel","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.juro.2008.10.001","article-title":"Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma","volume":"181","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0045","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1158\/1078-0432.CCR-07-4089","article-title":"Sunitinib for treatment of advanced renal cell cancer: primary tumor response","volume":"14","author":"van der Veldt","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.07.008_bib0050","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2009.24.7759","article-title":"Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma","volume":"28","author":"Cowey","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.juro.2010.05.041","article-title":"Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma","volume":"184","author":"Hellenthal","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0060","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma","volume":"27","author":"Jonasch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0065","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","article-title":"We should desist using RECIST, at least in GIST","volume":"25","author":"Benjamin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2214\/AJR.07.2077","article-title":"Imaging in metastatic renal cell carcinoma","volume":"189","author":"Griffin","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2214\/AJR.09.2941","article-title":"Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT","volume":"194","author":"Smith","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0080","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0085","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.juro.2008.10.021","article-title":"Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949","volume":"181","author":"Lara","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0090","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0095","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.07.008_bib0100","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2011.07.008_bib0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2011.01.038","volume":"59","author":"Krajewski","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.juro.2010.09.012","article-title":"The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy","volume":"185","author":"Choueiri","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2010.10.010","article-title":"Is tumor response important for renal carcinoma?","volume":"59","author":"Inman","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0120","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2214\/AJR.09.3456","article-title":"Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy","volume":"194","author":"Smith","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjc.6605567","article-title":"Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib","volume":"102","author":"van der Veldt","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2011.07.008_bib0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-010-0540-8","article-title":"Prognostic factors in renal cell carcinoma","volume":"28","author":"Volpe","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrurol.2009.102","article-title":"Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy","volume":"6","author":"Abel","year":"2009","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0140","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/annonc\/mdq563","article-title":"Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy","volume":"22","author":"Richey","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2011.07.008_bib0145","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/cncr.22260","article-title":"Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel","volume":"107","author":"Halbert","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.07.008_bib0150","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/annonc\/mdp466","article-title":"Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib","volume":"21","author":"Thiam","year":"2010","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811007457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811007457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T08:25:27Z","timestamp":1543652727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811007457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0302283811007457"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.07.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}